Analyst Price Target is $14.28
▲ +113.06% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Niagen Bioscience in the last 3 months. The average price target is $14.28, with a high forecast of $23.00 and a low forecast of $8.10. The average price target represents a 113.06% upside from the last price of $6.70.
Current Consensus is
Moderate Buy
The current consensus among 5 investment analysts is to moderate buy stock in Niagen Bioscience. This rating has held steady since September 2025, when it changed from a Buy consensus rating.
Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.
Read More
